AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32043347 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIEHPFED
Number of subjects: 2
Study 35174663 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg
Number of subjects: 145
Study 35174663 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no perindopril)
Number of subjects: 145
Study 35174663 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine 2.5 g thrice daily
Number of subjects: 145
Study 35174663 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no leucine)
Number of subjects: 145
Study 35174663 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of ACE inhibitors/ARBs
Number of subjects: 145
Study 34544253 — intervention group
Group type: EXPERIMENTAL
Intervention: PlayStation® video games (active distraction)
Number of subjects: 34
Study 34544253 — intervention group
Group type: COMPARATOR
Intervention: Cartoon film (passive distraction)
Number of subjects: 34
Study 34544253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active and passive distraction)
Number of subjects: 34
Study 32617000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with posturography for 10 sessions
Number of subjects: 40
Study 32617000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with posturography for 5 sessions
Number of subjects: 40
Study 32617000 — intervention group
Group type: COMPARATOR
Intervention: Both groups (10 sessions and 5 sessions)
Number of subjects: 40
Study 34216878 — intervention group
Group type: EXPERIMENTAL
Intervention: Li Maneuver
Number of subjects: 254
Study 34216878 — intervention group
Group type: COMPARATOR
Intervention: Gufoni Maneuver
Number of subjects: 254
Study 32594675 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple chronotherapy (combined total sleep deprivation, light therapy, and sleep phase advance) add-on to standard pharmacological treatment
Number of subjects: 0
Study 32594675 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological treatment
Number of subjects: 0
Study 35474627 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 7
Study 35474627 — intervention group
Group type: COMPARATOR
Intervention: Inpatient multimodal treatment (IMT)
Number of subjects: 7
Study 33865471 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 8719
Study 33865471 — intervention group
Group type: COMPARATOR
Intervention: 3-monthly ART dispensing
Number of subjects: 8719
Study 33865471 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly ART dispensing
Number of subjects: 8719
Study 33665919 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-based intervention
Number of subjects: 23
Study 34334898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg twice on day 1, then 400 mg once daily from day 2 to day 5
Number of subjects: 110
Study 34334898 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 110
Study 34334898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 110
Study 35144787 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-Expandable Stent (BES)
Number of subjects: 92
Study 35144787 — intervention group
Group type: COMPARATOR
Intervention: Self-Expandable Stent (SES)
Number of subjects: 92
Study 35144787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BES and SES
Number of subjects: 92
Study 34372928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutricia™ preOp® (400 mL) administered to the pre-op group after 10 hours of fasting.
Number of subjects: 81
Study 34372928 — intervention group
Group type: COMPARATOR
Intervention: Control group (no carbohydrate-enriched drink).
Number of subjects: 81
Study 34372928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pre-op and control) after 10 hours of fasting.
Number of subjects: 81
Study 34372928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pre-op and control) after fasting.
Number of subjects: 81
Study 34936159 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture classroom (TC)
Number of subjects: 36
Study 34936159 — intervention group
Group type: COMPARATOR
Intervention: Mobile application (APP)
Number of subjects: 36
Study 34936159 — intervention group
Group type: COMPARATOR
Intervention: Combination of both methods (TC-APP)
Number of subjects: 36
Study 34069907 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic vision training
Number of subjects: 73
Study 34069907 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 73
Study 34069907 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 73
Study 32618267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAp) administered during MDA/fMDA
Number of subjects: 336821
Study 35278154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive cognitive training
Number of subjects: 62
Study 35278154 — intervention group
Group type: COMPARATOR
Intervention: Educational training control
Number of subjects: 62
Study 33909185 — intervention group
Group type: COMPARATOR
Intervention: tofacitinib
Number of subjects: 0
Study 33909185 — intervention group
Group type: COMPARATOR
Intervention: upadacitinib
Number of subjects: 0
Study 35120577 — intervention group
Group type: EXPERIMENTAL
Intervention: High single dose of vitamin D (140,000 IU) followed by treatment as usual (TAU)
Number of subjects: 0
Study 35120577 — intervention group
Group type: COMPARATOR
Intervention: Placebo + treatment as usual (TAU)
Number of subjects: 0
Study 33828219 — intervention group
Group type: COMPARATOR
Intervention: Exploratory cohort patients measuring upper vertical lung length (uVLL), lower vertical lung length (lVLL), total vertical lung length (tVLL), and l/uVLL ratio on chest X-rays.
Number of subjects: 280
Study 33828219 — intervention group
Group type: COMPARATOR
Intervention: lVLL measurement
Number of subjects: 280
Study 33828219 — intervention group
Group type: COMPARATOR
Intervention: tVLL measurement
Number of subjects: 280
Study 33828219 — intervention group
Group type: COMPARATOR
Intervention: l/uVLL ratio measurement
Number of subjects: 280
Study 33899607 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear models (GLMs) without adjusting for covariates
Number of subjects: 0
Study 33899607 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment method proposed based on asymptotic results
Number of subjects: 0
Study 33899607 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly used generalized linear models (e.g., logistic regression, Poisson regression)
Number of subjects: 0
Study 34166402 — intervention group
Group type: EXPERIMENTAL
Intervention: Current asthma in 2016 (11.5%) compared to 2008 (9.3%)
Number of subjects: 2484
Study 34166402 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing up on a farm
Number of subjects: 2484
Study 34166402 — intervention group
Group type: EXPERIMENTAL
Intervention: Current allergic rhinitis (AR)
Number of subjects: 2484
Study 34166402 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking in 2016 (15.2%) compared to 2008 (20.3%)
Number of subjects: 2484
Study 34166402 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of electronic cigarettes in 2016 (4.8%)
Number of subjects: 2484
Study 34909972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 40 mg/day
Number of subjects: 73
Study 34909972 — intervention group
Group type: COMPARATOR
Intervention: Micronized vaginal progesterone 800 mg/day
Number of subjects: 73
Study 33987239 — intervention group
Group type: EXPERIMENTAL
Intervention: EGHB010
Number of subjects: 94
Study 33987239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 33399242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy without chemotherapy
Number of subjects: 0
Study 33234974 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomatic stapler
Number of subjects: 649
Study 33234974 — intervention group
Group type: COMPARATOR
Intervention: Needle arm (conventional thread)
Number of subjects: 649
Study 35475947 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized skill sequences (standard, strengths-prioritized, deficits-prioritized)
Number of subjects: 70
Study 35475947 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 sessions of treatment
Number of subjects: 70
Study 35475947 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of treatment
Number of subjects: 70
Study 34743682 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular moderate intensity exercise during pregnancy
Number of subjects: 855
Study 34743682 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 855
Study 36461040 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality session (10 minutes using a head-mounted VR device to watch and listen to a nature scene)
Number of subjects: 150
Study 36461040 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 33426575 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol mouth-rinse (MENT)
Number of subjects: 8
Study 33426575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (HOT)
Number of subjects: 8
Study 33426575 — intervention group
Group type: COMPARATOR
Intervention: Water mouth-rinse (CON)
Number of subjects: 8
Study 35439637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep First group (encoded word pairs at night before sleep)
Number of subjects: 56
Study 35439637 — intervention group
Group type: COMPARATOR
Intervention: Wake First group (encoded word pairs in the morning before a day of wakefulness)
Number of subjects: 56
Study 35439637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 33684772 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessing overdose
Number of subjects: 502
Study 33684772 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing overdose
Number of subjects: 502
Study 33684772 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to naloxone
Number of subjects: 502
Study 33684772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying naloxone
Number of subjects: 502
Study 33684772 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly injecting alone
Number of subjects: 502
Study 33684772 — intervention group
Group type: EXPERIMENTAL
Intervention: Others having naloxone when injecting
Number of subjects: 502
Study 35436174 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hearing support
Number of subjects: 136
Study 35436174 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 136
Study 34511091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular polynucleotides and hyaluronic acid (PNHA)
Number of subjects: 100
Study 34511091 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 100
Study 32412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment <2 years
Number of subjects: 259
Study 32412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment for 2 years
Number of subjects: 259
Study 32412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment >2 years
Number of subjects: 259
Study 32412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment (all groups)
Number of subjects: 259
Study 36335797 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Learning Environment (VRLE)
Number of subjects: 69
Study 36335797 — intervention group
Group type: COMPARATOR
Intervention: Traditional 2-dimensional images (Control)
Number of subjects: 69
Study 33974972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic hilar and celiac plexus nerve blocks
Number of subjects: 92
Study 33974972 — intervention group
Group type: COMPARATOR
Intervention: Standard intraprocedural local anesthetic, intra‐arterial lidocaine, and intravenous analgesia (Control)
Number of subjects: 92
Study 32522320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall technique (HT)
Number of subjects: 123
Study 32522320 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel crown (SSC)
Number of subjects: 123
Study 32522320 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified atraumatic restorative treatment (mART)
Number of subjects: 123
Study 35987550 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound intervention (IP + WBE), n=87
Number of subjects: 251
Study 35987550 — intervention group
Group type: COMPARATOR
Intervention: Information provision arm (IP), n=84
Number of subjects: 251
Study 35987550 — intervention group
Group type: COMPARATOR
Intervention: Psychological well-being enhancement arm (WBE), n=80
Number of subjects: 251
Study 33386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal muscular vibration (FMV) applied to flexor muscles of the upper limb (Group A)
Number of subjects: 28
Study 33386031 — intervention group
Group type: COMPARATOR
Intervention: Focal muscular vibration (FMV) applied to extensor muscles of the upper limb (Group B)
Number of subjects: 28
Study 33386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 28
Study 34544843 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) after wheat exposure
Number of subjects: 147
Study 34544843 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) at 6 months follow-up
Number of subjects: 147
Study 33212540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose Computed Tomography (LDCT) screening
Number of subjects: 0
Study 33212540 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT screening until the age of 80
Number of subjects: 0
Study 33212540 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping LDCT screening at age 75
Number of subjects: 0
Study 33212540 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction models based on smoking history, sex, and age
Number of subjects: 0
Study 32931375 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 11
Study 32931375 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 11
Study 32208168 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-5150 (2 mg)
Number of subjects: 62
Study 32208168 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-5150 (8.5 mg)
Number of subjects: 62
Study 32208168 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-5150 (2 mg) + INO-9012 (1 mg)
Number of subjects: 62
Study 32208168 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-5150 (8.5 mg) + INO-9012 (1 mg)
Number of subjects: 62
Study 32208168 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38 and perforin co-positive CD8 T cells
Number of subjects: 62
Study 35253707 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)
Number of subjects: 28
Study 35253707 — intervention group
Group type: COMPARATOR
Intervention: False kinesiotape (FKT)
Number of subjects: 28
Study 32447474 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib with HFS at any time
Number of subjects: 294
Study 32447474 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib with HFS in the first 2 cycles
Number of subjects: 294
Study 32447474 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib with varying severity of HFS
Number of subjects: 294
Study 32947608 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial and clinical features
Number of subjects: 106
Study 32947608 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial features only
Number of subjects: 106
Study 32947608 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial and bio-clinical features including fasting glycaemic measures
Number of subjects: 106
Study 36329519 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO6S
Number of subjects: 427
Study 36329519 — intervention group
Group type: COMPARATOR
Intervention: A6Sw/oI
Number of subjects: 427
Study 32105341 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + PDT
Number of subjects: 120
Study 32105341 — intervention group
Group type: COMPARATOR
Intervention: NaOCl
Number of subjects: 120
Study 32105341 — intervention group
Group type: COMPARATOR
Intervention: NaOCl + EDTA
Number of subjects: 120
Study 32105341 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + EDTA + PDT
Number of subjects: 120
Study 36349571 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP titration to the lowest driving pressure
Number of subjects: 207
Study 36349571 — intervention group
Group type: COMPARATOR
Intervention: Conventional low level of PEEP (4 cm H2O)
Number of subjects: 207
Study 36346936 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth lifestyle-coaching program (Liva)
Number of subjects: 340
Study 36346936 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 340
Study 32591439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive hypertension treatment (targeting systolic BP <120 mm Hg)
Number of subjects: 9361
Study 32591439 — intervention group
Group type: COMPARATOR
Intervention: Standard hypertension treatment (targeting systolic BP <140 mm Hg)
Number of subjects: 9361
Study 32591439 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining kidney function measured by eGFR
Number of subjects: 9361
Study 32591439 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident eGFR <60 ml/min per 1.73 m2
Number of subjects: 9361
Study 32591439 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and incident urinary ACR ≥30 mg/g
Number of subjects: 9361
Study 34657407 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine monitoring of cardiac troponin (cTn) levels during the first 48 hours post-operation in high-risk patients
Number of subjects: 0
Study 34657407 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cardiovascular drugs (aspirin, antihypertensives, statins)
Number of subjects: 0
Study 34657407 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 0
Study 34657407 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial injury detected before noncardiac surgery
Number of subjects: 0
Study 33722218 — intervention group
Group type: EXPERIMENTAL
Intervention: Family dinner ≥4 times/week
Number of subjects: 408
Study 33722218 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional meal category eaten with family ≥4 times/week
Number of subjects: 408
Study 33722218 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meals
Number of subjects: 408
Study 32203675 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation (graduated weightbearing at 2 weeks)
Number of subjects: 18
Study 32203675 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (weightbearing at 6 weeks)
Number of subjects: 18
Study 32203675 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Number of subjects: 18
Study 32203675 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 18
Study 32203675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 33994954 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS plus MT
Number of subjects: 18
Study 33994954 — intervention group
Group type: COMPARATOR
Intervention: sham iTBS plus MT
Number of subjects: 18
Study 33994954 — intervention group
Group type: COMPARATOR
Intervention: real MT
Number of subjects: 18
Study 32448722 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch supplementation (35 g/d)
Number of subjects: 0
Study 32448722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35921606 — intervention group
Group type: EXPERIMENTAL
Intervention: New cancer drugs
Number of subjects: 331
Study 35921606 — intervention group
Group type: COMPARATOR
Intervention: Initial indications
Number of subjects: 331
Study 34393120 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine/2.5% prilocaine topical anesthetic
Number of subjects: 0
Study 34393120 — intervention group
Group type: COMPARATOR
Intervention: Injection anesthetic
Number of subjects: 0
Study 34393120 — intervention group
Group type: EXPERIMENTAL
Intervention: L/P topical anesthetic
Number of subjects: 0
Study 35466800 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling program based on cognitive behavioural therapy (16 sessions)
Number of subjects: 22
Study 35466800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counselling program)
Number of subjects: 22
Study 32213303 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma suPAR level above 3.70 ng mL-1
Number of subjects: 1190
Study 34643947 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anthracycline plus ifosfamide (AI)
Number of subjects: 1001
Study 34643947 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology-tailored (HT) chemotherapy
Number of subjects: 1001
Study 36192605 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT bike
Number of subjects: 45
Study 36192605 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT short-treadmill
Number of subjects: 45
Study 36192605 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT long-treadmill
Number of subjects: 45
Study 36192605 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 32114806 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral arthroplasty (PFA)
Number of subjects: 64
Study 32114806 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 64
Study 34954837 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizers (ABHS)
Number of subjects: 62
Study 34954837 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfectant wipes
Number of subjects: 62
Study 34954837 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and soap
Number of subjects: 62
Study 33595901 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 1029
Study 33595901 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 1029
Study 33094898 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and passive muscle stretching exercises
Number of subjects: 28
Study 33017854 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 433
Study 33017854 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 433